Phase 2 N=13 Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds
Obesity, Morbid · Bariatric Surgery · Adolescent
Primary: Enrollment Rate — 19 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=75 Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1
HIV Infections
Primary: Proportion of Participants Experiencing a Grade 3 or Higher Adverse Event (AE) or Premature Discontinuation Due to an AE (Regardless of Grade) That is Related To Step 2…
Phase 2 N=137 Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
Multiple Myeloma
Primary: Overall Response Rate — 74.5 Percentage of Participants
Phase 2 N=53 Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS
Postural Orthostatic Tachycardia Syndrome
Primary: Change From Baseline to Week 24 in the COMPASS 31 (2-week Recall Version) — -14.369; -15.957 score on a scale
Phase 2 N=18 Trial of NanoPac Intratumoral Injection in Lung Cancer
Lung Cancer, Nonsmall Cell · Lung Cancer · Lung Cancer, Small Cell
Primary: Number of Participants With Treatment Emergent Adverse Events — 18 Participants
Phase 2 N=396 Quit Smoking Study for People Who Use E-Cigarettes
Nicotine Addiction · E-Cig Use · Quitting Smoking
Primary: Biochemically Confirmed 7-day Point-prevalence Cigarette Abstinence — 16; 26; 16; 16 Participants
Phase 2 N=85 Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer
Oropharynx Cancer
Primary: The Percentage of Patients With Local Regional Recurrence (LRR) of Disease — 2; 3 percentage of participants
Phase 2 N=10 Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI)
Spinal Cord Injuries · Tetraplegia · Paraplegia
Primary: Change in Muscle Mass Using Dual X-ray Absorptiometry (DXA) — -183.00; 1434.00 grams
Phase 2 N=46 A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
Advanced Solid Tumors
Primary: Part A: Number of Participants With Dose-limiting Toxicities (DLTs) Based on Common Terminology Criteria for Adverse Events (CTCAE) — 0; 0; 0; 2 Participants
Phase 2 N=36 A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Change From Baseline in the Peak Esophageal Intraepithelial Eosinophil Count at Week 4 (Mean) — -9.2; -31.6; -7.8 eosinophil count per high power field
Phase 2 N=195 A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease
Uncontrolled Hypertension · Chronic Kidney Diseases
Primary: Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) of Pooled CIN-107 and Placebo — -15.22; -7.15 Millimeters of mercury (mmHg) — p=0.003
Phase 2 N=7 Targeting IL-17A for Treatment-Resistant Depression
Major Depressive Disorder
Primary: Number of Participants Who Dropped-out — 0 Participants
Phase 2 N=48 A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease
Dry Eye Disease · Dry Eye Syndrome
Primary: Stage 1: Number of Participants With Adverse Events — 5; 1; 4; 2 Participants
Phase 2 N=10 Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus
Discoid Lupus Erythematosus
Primary: Mean Severity of Disease as Measured by the Investigator's Global Assessment — 1.4 score on a scale
Phase 2 N=322 Assessing Immune Response of Different COVID-19 Vaccines in Older Adults
Prevention of COVID-19
Primary: Antibody Titre Increase 14 Days After Study Vaccination Dose. — 100; 100; 78.46; 87.22 percentage of participants